Technology

Calgary Scientific Inc. announced the release of ResolutionMD 5.1. The latest software version enables physicians to make faster and more informed treatment decisions, by providing even greater access to medical images and information via Web and mobile devices.

Home June 18, 2015
Home
News | Antiplatelet and Anticoagulation Therapies

Atrial fibrillation patients on the anticoagulant dabigatran were more likely to adhere to the medication with appropriate patient selection and pharmacist-led monitoring, according to a study in the April 14 issue of JAMA. The study looked at patients who filled dabigatran prescriptions at Veterans Health Administration (VHA) sites, and found variability in patient medication adherence across sites.

Home June 18, 2015
Home
News | Stents

Stentys announced in April that it received CE Marking for its new Self-Apposing stent system ahead of plan. The designation will allow the company to market the new products in Europe and in all the other countries where this certification is recognized. The Xposition S stent officially launched at the EuroPCR conference on May 19, 2015.

Home June 18, 2015
Home
News | Cardiovascular Business

IMRIS Inc. received a letter May 26 from the NASDAQ Stock Market stating that it would be delisted and trading suspended on June 4. IMRIS said this was in accordance with Listing Rules 5101, 5110(b), and IM-5101-1. A Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC), which will remove the company's securities from listing and registration on The Nasdaq Stock Market.

Home June 18, 2015
Home
Technology

Toshiba America Medical Systems Inc. has received U.S. Food and Drug Administration (FDA) clearance for detector and computed tomography (CT) software enhancements for its Aquilion ONE family of CT systems. which are designed to offer customers the right technology to meet their business needs for improving patient safety, have received FDA clearance.

Home June 18, 2015
Home
Videos | Cardiovascular Ultrasound

Role of Interventional Echcardiography in Transcatheter Structural Heart Procedures — Rebecca Hahn, M.D., Columbia ...

Home June 17, 2015
Home
News | Stents Carotid

Karam Moon, M.D., winner of the DePuy Synthes Cerebrovascular Section Resident/Fellow Award, presented his research, The Myth of Restenosis after Carotid Angioplasy and Stenting, at the American Association of Neurological Surgeons (AANS) annual scientific meeting in May.

Home June 17, 2015
Home
Videos | Structural Heart

Interview with Ted Feldman, M.D., FACC, MSCAI, FESC, cardiac cath lab director, Evanston Hospital, North Shore Health ...

Home June 17, 2015
Home
Videos | Heart Valve Technology

Interview with Michael Reardon, M.D., professor of cardiothoracic surgery at DeBakey Heart and Vascular Center, and ...

Home June 17, 2015
Home
Videos | Heart Valve Technology

Interview with Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research ...

Home June 17, 2015
Home
News | Stents Drug Eluting

Stentys announced that the findings of the first Xposition clinical experience, as part of the SETUP trial, were presented at the EuroPCR conference in May. The results of this study were also published in the online edition of EuroIntervention.

Home June 17, 2015
Home
Videos | Heart Valve Technology

Interview with Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research ...

Home June 17, 2015
Home
Videos | Structural Heart

Interview with Charanjit Rihal, M.D., chief of cardiology and professor of medicine, Mayo Clinic, at the Transcatheter ...

Home June 17, 2015
Home
News | Pharmaceuticals

Merck announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with Vytorin (ezetimibe and simvastatin) to treatment with simvastatin alone. The trial assessed more than 18,000 patients presenting with acute coronary syndromes.

Home June 17, 2015
Home
News | Heart Valve Technology

St. Jude Medical Inc. announced the resumption of the company's U.S. investigational device exemption (IDE) trial evaluating the Portico transcatheter aortic valve implantation system. The Portico IDE trial originally launched in May 2014, and is designed to support U.S. approval of the Portico system.

Home June 17, 2015
Home
Subscribe Now